Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma

NK/T Cell Lymphoma Clinical Trial

Official title:
Study Evaluating the Safety and Efficacy of the Dexamethasone, Azacytidine, Pegaspargase, Tislelizumab With NK/T Cell Lymphoma

Status Not yet recruiting

Clinical Trial Summary

The optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been well-defined. This phase II study aimed to evaluate the efficacy and safety of Dexamethasone, azacytidine, Pegaspargase, Tislelizumab (DAPT) regimen for patients with newly diagnosed advanced stage ENKTL , non-upper aerodigestive tract NK/T- cell lymphoma（NUAT- NKTCL）and relapsed refractory NK/T cell lymphoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04899414
Study type	Interventional
Source	Peking University
Contact	Jun Zhu, Dr.
Phone	+86-13910333346
Email	zhu-jun@bjcancer.org
Status	Not yet recruiting
Phase	Phase 2
Start date	May 18, 2021
Completion date	October 18, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05627856` - A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL	Phase 1/Phase 2
Not yet recruiting	`NCT05208853` - An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma	Early Phase 1
Withdrawn	`NCT04230330` - Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma	Phase 1
Recruiting	`NCT04004637` - CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia	Phase 1
Completed	`NCT01660568` - Gemcitabine in NK/T Cell Lymphoma	N/A
Recruiting	`NCT04038411` - PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma	Phase 4